COMMUNIQUÉS West-GlobeNewswire
-
TogetherTuesday: Arizona Nonprofit Surpasses $6 Million for Childhood Blindness Research
23/06/2026 -
TOMI Reports Accelerating SteraMist Adoption as Ebola Outbreaks and Global Biosecurity Threats Drive Preparedness Spending
23/06/2026 -
Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
23/06/2026 -
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
23/06/2026 -
Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System
23/06/2026 -
IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification
23/06/2026 -
CoreHealth Announces Leadership Transition as Charles Martin Appointed Chief Executive Officer
23/06/2026 -
The XLH Network and Kyowa Kirin Launch the XLH Community Guidebook to Help People Navigate Lifelong Journey with XLH
23/06/2026 -
SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury
23/06/2026 -
Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Advancing Nanoparticle-Encapsulated PNKP Inhibitor in Oncology Space
23/06/2026 -
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
23/06/2026 -
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
23/06/2026 -
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
23/06/2026 -
Premier Health of America Announces CCAA Proceedings
23/06/2026 -
SRX Global Makes Strategic Investment in Clinical-Stage Biodefense Company, ARMR Sciences
23/06/2026 -
Corxel Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Trial of CX11 in Obese and Overweight U.S. Adults
23/06/2026 -
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas
23/06/2026 -
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel
23/06/2026 -
Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia
23/06/2026
Pages